2019_3q_omron_e
25/34 HCB Going for Zero(2)

【テロップ】
※各テロップ文字をクリックすると該当の場所がピンポイントで閲覧できます。



【ノート】
As a result of the revised guidelines, the number of patients diagnosed with hypertension in the US rose from 72.2 million to 103.3 million, an increase of roughly 30 million patients in one fell swoop. This is merely one example from the US. HCB continues to see its markets grow in both emerging countries as well as developed countries. BPMs are medical devices that are approved by regulatory authorities, such as the FDA, in each country. Although demand is rising, barriers to entry are extremely high, making it very challenging for new entrants. We will continue to invest selectively in order to ensure we capture growth opportunities.